METHODS: Manual retrospective chart review of 1,218 patients with EoE identified by ICD-9/10 codes from the University of Pennsylvania Health Systems. Parameters include age, gender, ethnicity, smoking history, family history of EoE, age at diagnosis, presenting symptom, number of eosinophils/high-powered field (Eos/HPF) on initial and most recent biopsies, peripheral absolute eosinophil count (AEC), serum IgE level, history of food impaction, stricture requiring dilatation, EoE therapy, presence of comorbid atopic or other conditions.
RESULTS: The current cohort is predominantly male (64%), Caucasian (88%) with an average age of 32 years that presented with dysphagia (57%) on diagnosis, 3.5% with family history of EoE (all first degree relatives). On presentation, the average EGD had 50 Eos/HPF; the maximum AEC (mean-472) and IgE (mean-330). Endoscopically, 59% had impaction (38% required endoscopic removal), 42% had strictures/fibrosis (75% underwent dilatation). Therapy used: diet and medical (22%), medical only (71%), and diet only (3%). For atopic conditions, there was asthma (33%); eczema (17%); IgE-mediated food allergy-not including PFAS-(26%); PFAS (31% ); SAR/PAR (74%); medication allergy (25%); anaphylaxis (16%); and Latex allergy (5%). For comorbid conditions, autoimmune disease (9%); H. pylori (3%); psychiatric comorbidity (14%); and never-smokers (80%).
CONCLUSIONS: This EoE cohort shares features seen with pediatric cohorts with increased PFAS and other atopic conditions compared to national averages.